The Combination of a BCL-xL PROTAC and an mTOR Inhibitor Sensitizes Pancreatic Ductal Adenocarcinoma to KRASG12D Inhibitor Treatment

作者
Javed Miyan,Vignesh Vudatha,Lin Cao,Peiyi Zhang,Guangrong Zheng,Lei Zheng,Jose Trevino,Daohong Zhou,Sajid Khan
出处
期刊:Cancers [Multidisciplinary Digital Publishing Institute]
卷期号:18 (6): 920-920 被引量:2
标识
DOI:10.3390/cancers18060920
摘要

BACKGROUND/OBJECTIVES: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with a five-year survival rate of approximately 13%, partly because of limited treatment options and resistance to therapies. Although the recently discovered KRAS G12D inhibitor MRTX1133 has shown promising efficacy in preclinical models, its clinical efficacy as a single agent is expected to be limited, as is the case with KRAS G12C inhibitors. Therefore, in this study, we evaluated potential combination strategies to enhance the therapeutic effect of MRTX1133. We combined MRTX1133 with the BCL-xL proteolysis-targeting chimera (PROTAC) DT2216 and the mTOR inhibitor everolimus. METHODS: The sensitization of MRTX1133 by the combination of DT2216 + everolimus was tested in KRAS G12D-mutant PDAC cell lines using colony formation and apoptosis assays. The effects of MRTX1133 and/or DT2216 + everolimus on KRAS signaling and BCL-2 family proteins were assessed by immunoblotting and/or RT-PCR. The functional roles of BIM/NOXA were elucidated via immunoprecipitation (IP) and siRNA knockdown. Triple combination efficacy was evaluated in AsPC1 parental and MRTX1133-resistant xenografts, with pharmacodynamic effects confirmed by immunoblotting and immunohistochemistry. RESULTS: The triple combination leads to significantly greater colony growth inhibition and apoptosis induction as compared with single agents or two-drug combinations in multiple KRAS G12D-mutant PDAC cell lines. Mechanistically, MRTX1133 treatment increased BIM and decreased NOXA levels, and the combination of DT2216/everolimus simultaneously enhanced BIM release and stabilized NOXA. In vivo, DT2216/everolimus combination significantly potentiated the anti-tumor activity of MRTX1133 in the AsPC1 PDAC xenograft model. Furthermore, the triple combination effectively overcame acquired MRTX1133 resistance in vitro and in the AsPC1 xenograft model. CONCLUSIONS: Collectively, our findings suggest that the combination of DT2216/everolimus potentiates the anti-tumor efficacy of MRTX1133 associated with enhanced apoptosis induction and inhibition of compensatory survival signaling.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
只要一点点的应助被舒心易烟采纳,获得10
1秒前
科研通AI65的应助被Mmxn采纳,获得10
1秒前
1秒前
2秒前
2秒前
Teletubbies的应助被Gally采纳,获得20
2秒前
田様的应助被zhangyaoyang采纳,获得10
3秒前
甜甜圈发布了新的文献求助10
3秒前
江北小赵发布了新的文献求助10
3秒前
4秒前
you完成签到,获得积分10
4秒前
4秒前
Sheng完成签到,获得积分10
4秒前
Ava的应助被初景采纳,获得10
5秒前
zhc发布了新的文献求助10
5秒前
5秒前
ZYK完成签到,获得积分10
5秒前
踏实的弼完成签到,获得积分10
6秒前
wei发布了新的文献求助10
6秒前
科目三的应助被甜瓜甜采纳,获得10
6秒前
6秒前
深情安青的应助被陈欣怡采纳,获得10
6秒前
M3L2发布了新的文献求助10
6秒前
汉堡包的应助被欧文采纳,获得10
6秒前
天天快乐的应助被霁月采纳,获得10
6秒前
李健的小迷弟的应助被霁月采纳,获得10
7秒前
汉堡包的应助被霁月采纳,获得10
7秒前
斯文败类的应助被霁月采纳,获得10
7秒前
HWB发布了新的文献求助10
7秒前
Antirick发布了新的文献求助10
7秒前
天天快乐的应助被小鱼采纳,获得10
8秒前
8秒前
板蓝根完成签到,获得积分10
8秒前
收声发布了新的文献求助200
8秒前
科研通AI6.3的应助被牧百川采纳,获得10
9秒前
小苏打完成签到,获得积分10
9秒前
吴海发布了新的文献求助10
10秒前
10秒前
思源的应助被lijie采纳,获得10
10秒前
Hello的应助被nininic采纳,获得10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183046
求助须知:如何正确求助?哪些是违规求助? 9572370
关于积分的说明 21824411
捐赠科研通 7779694
什么是DOI,文献DOI怎么找? 3433792
关于科研通互助平台的介绍 2558024
邀请新用户注册赠送积分活动 2479971